The metabolic and pharmacologic bases for treating atherogenic dyslipidaemia

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 28, Issue 3, 2014, Pages 369-385

  Chan, Dick C ^a   Barrett, P Hugh R ^a,b   Watts, Gerald F ^a,c  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c ROYAL PERTH HOSPITAL   (Australia)

Author keywords

Cardiovascular disease; Hypertriglyceridaemia; Lifestyle modification; Low HDL cholesterol; Metabolic syndrome; Pharmacological treatment; Treatment target

Indexed keywords

APOLIPOPROTEIN B; CHOLESTEROL ABSORPTION INHIBITOR; EZETIMIBE; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN; NICOTINIC ACID; OMEGA 3 FATTY ACID; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN; ANTILIPEMIC AGENT; LIPOPROTEIN;

ARTICLE; ATHEROGENIC DYSLIPIDEMIA; CARDIOVASCULAR RISK; CATABOLISM; CLINICAL TRIAL (TOPIC); DIET RESTRICTION; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; EXERCISE; GENETICS; HUMAN; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LIPOPROTEIN METABOLISM; OBESITY; PHENOTYPE; PHYSICAL ACTIVITY; WEIGHT REDUCTION; ATHEROSCLEROSIS; BLOOD; CARDIOVASCULAR DISEASES; COMPLICATION; DIET; DRUG EFFECTS; DYSLIPIDEMIAS; GENETIC PREDISPOSITION; LIFESTYLE; METABOLIC SYNDROME X; METABOLISM; RISK FACTOR;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; DIET; DYSLIPIDEMIAS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOLIPIDEMIC AGENTS; LIFE STYLE; LIPOPROTEINS; METABOLIC SYNDROME X; RISK FACTORS;

EID: 84901318325     PISSN: 1521690X     EISSN: 15321908     Source Type: Journal    
DOI: 10.1016/j.beem.2013.10.001     Document Type: Review

References (122)

1. R.M. Krauss, and Y.A. Kesaniemi Cardiovascular disease and hyperlipidaemia Current Opinion in Lipidology 5 1994 249 251
2. C. Baigent, A. Keech, and P.M. Kearney et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins Lancet 366 2005 1267 1278
3. B. Mihaylova, J. Emberson, and L. Blackwell et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials Lancet 380 2012 581 590
4. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report Circulation 106 2002 3143 3421
5. J.D. Brunzell, M. Davidson, and C.D. Furberg et al. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation Diabetes Care 31 2008 811 822
6. J.C. Fruchart, F. Sacks, and M.P. Hermans et al. The residual risk reduction initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia American Journal of Cardiology 102 Suppl. 2008 1 34
7. K.G. Alberti, R.H. Eckel, and S.M. Grundy et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity Circulation 120 2009 1640 1645
8. M.A. Austin, M.C. King, and K.M. Vranizan et al. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk Circulation 82 1990 495 506
9. M. Miller, N.J. Stone, and C. Ballantyne et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association Circulation 123 2011 2292 2333
10. M.J. Chapman, H.N. Ginsberg, and P. Amarenco et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management European Heart Journal 32 2011 1345 1361
11. D.F. Wyszynski, D.M. Waterworth, and P.J. Barter et al. Relation between atherogenic dyslipidemia and the Adult Treatment Program-III definition of metabolic syndrome (Genetic Epidemiology of Metabolic Syndrome Project) American Journal of Cardiology 95 2005 194 198
12. C.T. Johansen, and R.A. Hegele Using Mendelian randomization to determine causative factors in cardiovascular disease Journal of Internal Medicine 273 2013 44 47
13. A.B. Jørgensen, R. Frikke-Schmidt, and A. SodeWest et al. Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction European Heart Journal 34 2013 1826 1833
14. D.B. Zilversmit Atherogenesis: a postprandial phenomenon Circulation 60 1979 473 485
15. G.F. Watts, and F. Karpe Triglycerides and atherogenic dyslipidaemia: extending treatment beyond statins in the high-risk cardiovascular patient Heart 97 2011 350 356
16. J.P. Despres, I. Lemieux, and G.R. Dagenais et al. HDL-cholesterol as a marker of coronary heart disease risk: the Quebec cardiovascular study Atherosclerosis 153 2000 263 272
17. G. Assman, and H. Schulte Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary disease (the PROCAM experience) American Journal of Cardiology 70 1992 733 737
18. The ACCORD Study Group Effects of combination lipid therapy in type 2 diabetes mellitus New England Journal of Medicine 362 2010 1563 1574
19. W.A. van der Steeg, I. Holme, and S.M. Boekholdt et al. High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies Journal of American College of Cardiology 51 2008 634 642
20. A. Kontush, and M.J. Chapman Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis Pharmacological Reviews 58 2006 342 374
21. D.C. Chan, and G.F. Watts Apolipoproteins as coronary risk managers: towards a more rationale assessment of dyslipidaemias Quarterly Journal of Medicine 99 2006 277 287
22. K.K. Berneis, and R.M. Krauss Metabolic origins and clinical significance of LDL heterogeneity Journal of Lipid Research 43 2002 1363 1379
23. C.J. Packard Triacylglycerol-rich lipoproteins and the generation of small, dense low-density lipoprotein Biochemical Society Transactions 31 2003 1066 1069
24. R.M. Krauss Lipoprotein subfractions and cardiovascular disease risk Current Opinion in Lipidology 21 2010 305 311
25. W. Lu, H.E. Resnick, and K.A. Jablonski et al. Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: the strong heart study Diabetes Care 26 2003 16 23
26. Y. Cui, R.S. Blumenthal, and J.A. Flaws et al. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality Archives of Internal Medicine 161 2001 1413 1419
27. A.D. Sniderman, K. Williams, and M.J. McQueen et al. When is equal not equal? Journal of Clinical Lipidology 4 2010 83 88
28. L. Iselius Analysis of family resemblance for lipids and lipoproteins Clinical Genetics 15 4 Apr 1979 300 306
29. C. Johansen, and R. Hegele The complex genetic basis of plasma triglycerides Current Atherosclerosis Reports 14 2012 227 234
30. A.F. Ayyobi, S.H. McGladdery, and M.J. McNeely et al. Small, dense LDL and elevated apolipoprotein B are the common characteristics for the three major lipid phenotypes of familial combined hyperlipidemia Arteriosclerosis, Thrombosis, and Vascular Biology 23 2003 1289 1294
31. K. Musunuru, M. Orho-Melander, and M.P. Caulfield et al. Ion mobility analysis of lipoprotein subfractions identifies three independent axes of cardiovascular risk Arteriosclerosis, Thrombosis, and Vascular Biology 29 2009 1975 1980
32. D.C. Chan, P.H.R. Barrett, and G.F. Watts Dyslipidemia in visceral obesity: mechanisms, implications, and therapy American Journal of Cariovascular Drugs 4 2004 227 246
33. T.A. André, and J.P. Després Pathophysiology of human visceral obesity: an update Physiolological Reviews 93 2013 359 404
34. M. Matsumoto, S. Han, and T. Kitamura et al. Dual role of transcription factor FoxO1 in controlling hepatic insulin sensitivity and lipid metabolism Journal of Clinical Investigation 116 2006 2464 2472
35. M.S. Brown, and J.L. Goldstein Selective verse total insulin resistance Cell Metabolism 7 2008 95 96
36. K. Uyeda, and J.J. Repa Carbohydrate response element binding protein, ChREBP, a transcription factor coupling hepatic glucose utilization and lipid synthesis Cell Metabolism 4 2006 107 110
37. Y. Ido-Kitamura, T. Sasaki, and M. Kobayashi et al. Hepatic FoxO1 integrates glucose utilization and lipid synthesis through regulation of Chrebp O-Glycosylation PLoS One 7 2012 e47231
38. J.D. Horton, J.L. Goldstein, and M.S. Brown SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver Journal of Clinical Investigation 109 2002 1125 1131
39. D.C. Chan, M.M. Chen, and E.M.M. Ooi et al. An ABC of apolipoprotein C-III: a clinically useful new cardiovascular risk factor? International Journal of Clinical Practice 62 2008 799 809
40. J. Altomonte, L. Cong, and S. Harbaran et al. Foxo1 mediates insulin action on apoC-III and triglyceride metabolism Journal of Clinical Investigation 114 2004 1493 1503
41. Z. Yao Human apolipoprotein C-III - a new intrahepatic protein factor promoting assembly and secretion of very low density lipoproteins Cardiovascular & Hematological Disorders Drug Targets 12 2012 133 140
42. D.C. Chan, G.F. Watts, and T.G. Redgrave et al. Apolipoprotein B100 kinetics in visceral obesity: associations with plasma apolipoprotein CIII concentrations Metabolism 51 2002 1041 1046
43. D.C. Chan, M.N. Nguyen, and G.F. Watts et al. Plasma apolipoprotein C-III transport in centrally obese men: associations with very low-density lipoprotein apolipoprotein B and high-density lipoprotein apolipoprotein A-I metabolism Journal of Clinical Endocrinology and Metabolism 93 2008 557 564
44. D.C. Chan, G.F. Watts, and M.N. Nguyen et al. Apolipoproteins C-III and A-V as predictors of VLDL-triglyceride and apolipoprotein B-100 kinetics Arteriosclerosis, Thrombosis, and Vascular Biology 26 2006 590 596
45. D.C. Chan, G.F. Watts, and S.K. Gan et al. Nonalcoholic fatty liver disease as the transducer of hepatic oversecretion of very-low-density lipoprotein-apolipoprotein B-100 in obesity Arteriosclerosis, Thrombosis, and Vascular Biology 30 2010 1043 1050
46. G.F. Watts, D.C. Chan, and P.H. Barrett et al. Fat compartments and apolipoprotein B-100 kinetics in overweight-obese men Obesity Research 11 2003 152 159
47. S.H. Choi, and H.N. Ginsberg Increased very low density lipoprotein (VLDL) secretion, hepatic steatosis, and insulin resistance Trends in Endocrinology and Metabolism 22 2011 353 363
48. M. Adiels, S.O. Olofsson, and M.R. Taskinen et al. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome Arteriosclerosis, Thrombosis, and Vascular Biology 28 2008 1225 1236
49. S. Rashid, T. Watanabe, and T. Sakaue et al. Mechanisms of HDL lowering in insulin resistant, hypertriglyceridemic states: the combined effect of HDL triglyceride enrichment and elevated hepatic lipase activity Clinical Biochemistry 36 2003 421 429
50. G.F. Watts, P.H.R. Barrett, and J. Ji et al. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome Diabetes 52 2003 803 811
51. D.C. Chan, P.H.R. Barrett, and E.M.M. Ooi et al. Very-low density lipoprotein metabolism and plasma adiponectin as predictors of high-density lipoprotein apolipoprotein A-I kinetics in obese and non-obese men Journal of Clinical Endocrinology and Metabolism 94 2009 989 997
52. D.C. Chan, G.F. Watts, and T.W.K. Ng et al. Adiponectin and other adipocytokines as predictors of markers of triglyceride-rich lipoprotein metabolism Clinical Chemistry 51 2005 578 585
53. T.W.K. Ng, G.F. Watts, and M.S. Farvid et al. Adipocytokines and VLDL metabolism: independent regulatory effects of adiponectin, insulin resistance and fat compartments on VLDL apoB-100 kinetics? Diabetes 54 2005 795 802
54. J.G. Schneider, M. von Eynatten, and S. Schiekofer et al. Low plasma adiponectin levels are associated with increased hepatic lipase activity in vivo Diabetes Care 28 2005 2181 2186
55. S. Tiyyagura, and D. Smith Standard lipid profile Clinical Laboratory Medicine 26 2006 707 732
56. American Diabetes Association Prevention and management of diabetes complications Diabetes Care 35 Suppl. 1 2012 S28 S38
57. M.H. Davidson, C.M. Ballantyne, and T.A. Jacobson et al. Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists Journal of Clinical Lipidology 5 2011 338 367
58. A.M. Dattilo, and P.M. Kris-Etherton Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis American Journal of Clinical Nutrition 56 1992 320 328
59. T.W. Ng, G.F. Watts, and P.H. Barrett et al. Effect of weight loss on LDL and HDL kinetics in the metabolic syndrome: association with changes in plasma retinol-binding protein-4 and adiponectin levels Diabetes Care 30 2007 2945 2950
60. D.C. Chan, G.F. Watts, and T.W.K. Ng et al. Effect of weight loss on markers of triglyceride-rich lipoprotein metabolism in the metabolic syndrome European Journal of Clinical Investigation 38 2008 743 751
61. R.M. Krauss Atherogenic lipoprotein phenotype and diet-gene interactions Journal of Nutrition 131 2001 340S 343S
62. W.C. Knowler, E. Barrett-Connor, and S.E. Fowler et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin New England Journal of Medicine 346 2002 393 403
63. C. Couillard, J.P. Despres, and B. Lamarche et al. Effects of endurance exercise training on plasma HDL cholesterol levels depend on levels of triglycerides: evidence from men of the Health, Risk Factors, Exercise Training and Genetics (HERITAGE) Family Study Arteriosclerosis, Thrombosis, and Vascular Biology 21 2001 1226 1232
64. R.W. Braith, and K.J. Stewart Resistance exercise training: its role in the prevention of cardiovascular disease Circulation 113 2006 2642 2650
65. Y.E. Tsekouras, F. Magkos, and K.I. Prentzas et al. A single bout of whole-body resistance exercise augments basal VLDL-triacylglycerol removal from plasma in healthy untrained men Clinical Science 116 2009 147 156
66. F. Magkos, D.C. Wright, and B.W. Patterson et al. Lipid metabolism response to a single, prolonged bout of endurance exercise in healthy young men American Journal of Physiology Endocrinology and Metabolism 290 2006 355 362
67. S. Alam, M. Stolinski, and C. Pentecost et al. The effect of a six-month exercise program on very low-density lipoprotein apolipoprotein B secretion in type 2 diabetes Journal of Clinical Endocrinology and Metabolism 89 2004 688 694
68. M. Stolinski, S. Alam, and N.C. Jackson et al. Effect of 6-month supervised exercise on low-density lipoprotein apolipoprotein B kinetics in patients with type 2 diabetes mellitus Metabolism 57 2008 608 614
69. P.D. Thompson, S.M. Yurgalevitch, and M.M. Flynn et al. Effect of prolonged exercise training without weight loss on high-density lipoprotein metabolism in overweight men Metabolism 46 1997 217 223
70. R.R. Wing, P. Bolin, and F.L. Brancati et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes New England Journal of Medicine 369 2013 145 154
71. E.A. Stein, M. Lane, and P. Laskarzewski Comparison of statins in hypertriglyceridemia American Journal of Cardiology 81 1998 66B 69B
72. D.C. Chan, G.F. Watts, and P.H.R. Barrett et al. Effect of atorvastatin on chylomicron remnant metabolism in visceral obesity: a study employing a new stable isotope breath test Journal of Lipid Research 43 2002 706 712
73. D.C. Chan, G.F. Watts, and P.H.R. Barrett et al. Mechanism of action of an HMG CoA reductase inhibitor on apolipoprotein B-100 kinetics in visceral obesity Journal of Clinical Endocrinology and Metabolism 87 2002 2283 2289
74. B. Verges, E. Florentin, and S. Baillot-Rudoni et al. Effects of 20 mg rosuvastatin on VLDL1-, VLDL2-, IDL- and LDL-apoB kinetics in type 2 diabetes Diabetologia 51 2008 1382 1390
75. E.M.M. Ooi, P.H. Barrett, and D.C. Chan et al. Dose-dependent effect of rosuvastatin on apolipoprotein B-100 kinetics in the metabolic syndrome Atherosclerosis 197 2008 139 146
76. G.F. Watts, D.C. Chan, and P.H. Barrett et al. Effect of a statin on hepatic apolipoprotein B-100 secretion and plasma campesterol levels in the metabolic syndrome International Journal of Obesity and Related Metabolic Disorders 27 2003 862 865
77. D.C. Chan, G.F. Watts, and M.N. Nguyen et al. Factorial study of the effect of n-3 fatty acid supplementation and atorvastatin on the kinetics of HDL apolipoproteins A-I and apoA-II in men with abdominal obesity American Journal of Clinical Nutrition 84 2006 37 43
78. E.M.M. Ooi, G.F. Watts, and P.J. Nestel et al. Dose-dependent regulation of high-density lipoprotein metabolism with rosuvastatin in the metabolic syndrome Journal of Clinical Endocrinology and Metabolism 93 2008 430 437
79. B.F. Asztalos, K.V. Horvath, and J.R. McNamara et al. Effects of atorvastatin on the HDL subpopulation profile of coronary heart disease patients Journal of Lipid Research 43 2002 1701 1707
80. F.M. Sacks, V.J. Carey, and J.C. Fruchart Combination lipid therapy in type 2 diabetes New England Journal of Medicine 363 2010 692 695
81. B. Staels, J. Dallongeville, and J. Auwerx et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism Circulation 98 1998 2088 2093
82. D.C. Chan, G.F. Watts, and E.M.M. Ooi et al. Atorvastatin and fenofibrate have comparable effects on VLDL-apolipoprotein C-III kinetics in men with the metabolic syndrome Arteriosclerosis, Thrombosis, and Vascular Biology 28 2008 1831 1837
83. D.C. Chan, G.F. Watts, and E.M.M. Ooi et al. Regulatory effects of fenofibrate and atorvastatin on lipoprotein A-I and lipoprotein A-I: A-II kinetics in the metabolic syndrome Diabetes Care 32 2009 2111 2113
84. M.J. Chapman, J.S. Redfern, and M.E. McGovern et al. Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk Pharmacology & Therapeutics 126 2010 314 345
85. V.S. Kamanna, and M.L. Kashyap Mechanism of action of niacin on lipoprotein metabolism Current Atherosclerosis Reports 2 2000 26 46
86. S. Lamon-Fava, M.R. Diffenderfer, and P.H.R. Barrett et al. Extended-release niacin alters the metabolism of plasma apolipoprotein (apo) A-I and apoB-containing lipoproteins Arteriosclerosis, Thrombosis, and Vascular Biology 28 2008 1672 1678
87. J.W.A. van der Hoorn, W. de Haan, and J.F.P. Berbee et al. Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE*3Leiden.CETP mice Arteriosclerosis, Thrombosis, and Vascular Biology 28 2008 2016 2022
88. The AIM-HIGH Investigators Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy New England Journal of Medicine 365 2011 2255 2267
89. HPS2-THRIVE Collaborative Group HPS2-THRIVE randomized placebo-controlled trial in 25,673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment European Heart Journal 34 2013 1279 1291
90. J.R. Guyton, A.E. Slee, and T. Anderson et al. Relation of lipoprotein levels to cardiovascular events in the Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes (AIM-HIGH) trial Journal of American College of Cardiology 62 17 2013 1580 1584
91. A. Pandor, R.M. Ara, and I. Tumur et al. Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials Journal of Internal Medicine 265 2009 568 580
92. J.L. Fleg, M. Mete, and B.V. Howard et al. Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial Journal of American College of Cardiology 52 2008 2198 2205
93. J.J. Kastelein, F. Akdim, and E.S.G. Stroes et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia New England Journal of Medicine 358 2008 1431 1443
94. C. Baigent, M.J. Landray, and C. Reith et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial Lancet 377 2011 2181 2192
95. T. Nakamura, M. Hirano, and Y. Kitta et al. A comparison of the efficacy of combined ezetimibe and statin therapy with doubling of statin dose in patients with remnant lipoproteinemia on previous statin therapy Journal of Cardiology 60 2012 12 17
96. M. Rizzo, G.B. Rini, and G.A. Spinas et al. The effects of ezetimibe on LDL-cholesterol: quantitative or qualitative changes? Atherosclerosis 204 2009 330 333
97. D.C. Chan, G.F. Watts, and S.K. Gan et al. Effect of ezetimibe on hepatic fat, inflammatory markers, and apolipoprotein B-100 kinetics in insulin-resistant obese subjects on a weight loss diet Diabetes Care 33 2010 1134 1139
98. L.A. Leiter, D.J. Betteridge, and M. Farnier et al. Lipid-altering efficacy and safety profile of combination therapy with ezetimibe/statin vs. statin monotherapy in patients with and without diabetes: an analysis of pooled data from 27 clinical trials Diabetes, Obesity and Metabolism 13 2011 615 628
99. R.M. Califf, Y. Lokhnygina, and C.P. Cannon et al. An update on the IMProved reduction of outcomes: Vytorin Efficacy International trial (IMPROVE-IT) design American Heart Journal 159 2010 705 709
100. D. Mozaffarian, and J.H.Y. Wu Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events Journal of American College of Cardiology 58 2011 2047 2067
101. GISSI-Prevenzione Investigators Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial Lancet 354 1999 447 455
102. M. Yokoyama, H. Origasa, and M. Matsuzaki et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis Lancet 369 2007 1090 1098
103. ORIGIN Trial Investigators n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia New England Journal of Medicine 367 2012 309 318
104. Risk and Prevention Study Collaborative Group n-3 fatty acids in patients with multiple cardiovascular risk factors New England Journal of Medicine 368 2013 1800 1808
105. B. Oelrich, A. Dewell, and C.D. Gardner Effect of fish oil supplementation on serum triglycerides, LDL cholesterol and LDL subfractions in hypertriglyceridemic adults Nutrition, Metabolism and Cardiovascular Diseases 23 2013 350 357
106. C.M. Ballantyne, H.E. Bays, and J.J. Kastelein et al. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study) American Journal of Cardiology 110 2012 984 992
107. P.T. Price, C.M. Nelson, and S.D. Clarke Omega-3 polyunsaturated fatty acid regulation of gene expression Current Opinion in Lipidology 11 2000 3 7
108. D.C. Chan, G.F. Watts, and T.A. Mori et al. Randomized controlled trial of the effect of n-3 fatty acids supplementation on apolipoprotein B-100 and chylomicron remnant metabolism in visceral obesity American Journal of Clinical Nutrition 77 2003 300 309
109. K. Ouguerram, C. Maugeais, and J. Gardette et al. Effect of n-3 fatty acids on metabolism of apoB100-containing lipoprotein in type 2 diabetic subjects British Journal of Nutrition 96 2006 100 106
110. K.M. Slivkoff-Clark, A.P. James, and J. Mamo The chronic effects of fish oil with exercise on postprandial lipaemia and chylomicron homeostasis in insulin resistant viscerally obese men Nutrition & Metabolism 9 2012 9
111. D.C. Chan, G.F. Watts, and P.H.R. Barrett et al. Regulatory effects of HMGCoA reductase inhibitor and fish oils on apolipoprotein B100 kinetics with insulin resistant obese male subjects with dyslipidaemia Diabetes 51 2002 2377 2386
112. T.A. Jacobson Combination lipid-altering therapy: an emerging treatment paradigm for 21st century Current Atherosclerosis Reports 3 2001 373 382
113. A.C. Keech, P. Mitchell, and P.A. Summanen et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial Lancet 370 2007 1687 1697
114. E.Y. Chew, W.T. Ambrosius, and M.D. Davis et al. Effects of medical therapies on retinopathy progression in type 2 diabetes New England Journal of Medicine 363 2010 233 244
115. M. Rubenfire, R.D. Brook, and R.S. Rosenson Treating mixed hyperlipidemia and the atherogenic lipid phenotype for prevention of cardiovascular events American Journal of Medicine 123 2010 892 898
116. M.H. Davidson Combination therapy for dyslipidemia: safety and regulatory considerations American Journal of Cardiology 90 2002 50K 60K
117. C.R. Harper, and T.A. Jacobson Evidence-based management of statin myopathy Current Atherosclerosis Reports 12 2010 322 330
118. W.M. Mamouya, D. Frid, and M. Rocco et al. Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience American Heart Journal 166 2013 597 603
119. A.A. Carter, T. Gomes, and X. Camacho et al. Risk of incident diabetes among patients treated with statins: population based study British Medical Journal 346 2013 2610
120. R. Peto, J. Emberson, and M. Landray et al. Analyses of cancer data from three ezetimibe trials New England Journal of Medicine 359 2008 1357 1366
121. T.M. Brasky, A.K. Darke, and X. Song et al. Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial Journal of the National Cancer Institute 105 2013 1132 1141
122. J. Pang, D.C. Chan, and P.H. Barrett et al. Postprandial dyslipidaemia and diabetes: mechanistic and therapeutic aspects Current Opinion in Lipidology 23 2012 303 309